On 20 Nov 2025, Senores Pharmaceuticals touched an intraday peak of ₹829.75, representing a 4.8% rise during the trading session. This surge brought the stock within 0.68% of its 52-week high of ₹831.65, underscoring sustained upward movement over the past year. The closing price demonstrated a day-on-day change of 4.36%, notably outperforming the broader Sensex index, which recorded a 0.64% change on the same day.
Examining the stock's relative performance, Senores Pharmaceuticals outpaced its sector by 4.42% on the day, highlighting its strength within the Pharmaceuticals & Biotechnology industry. The stock is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a positive trend across short, medium, and long-term horizons.
Fundamentals that don't lie! This Small Cap from Trading shows consistent growth and price strength over time. A reliable pick you can truly count on.
- - Strong fundamental track record
- - Consistent growth trajectory
- - Reliable price strength
Looking at the performance over various time frames, Senores Pharmaceuticals has demonstrated notable resilience and strength. Over the past week, the stock recorded a 4.13% change compared to the Sensex's 1.48%. The one-month period saw a 13.92% movement for Senores Pharmaceuticals, significantly ahead of the Sensex's 1.62%. Over three months, the stock's performance stood at 15.88%, while the Sensex posted 4.73% during the same period.
Year-to-date figures reveal a 45.24% change for Senores Pharmaceuticals, substantially exceeding the Sensex's 9.72% gain. However, the stock's one-year, three-year, five-year, and ten-year performances are recorded as 0.00%, which may indicate data unavailability or a reset in tracking metrics for these periods. In contrast, the Sensex posted gains of 10.51% over one year, 39.03% over three years, 95.37% over five years, and 231.42% over ten years, providing a benchmark for broader market trends.
Market capitalisation grading places Senores Pharmaceuticals at a level 3, reflecting its standing within the small-cap segment of the Pharmaceuticals & Biotechnology sector. The stock's recent trading activity and price movements suggest a phase of consolidation and strength, supported by positive market sentiment and sectoral dynamics.
Why settle for Senores Pharmaceuticals ? SwitchER evaluates this Pharmaceuticals & Biotechnology small-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Senores Pharmaceuticals' journey to this all-time high has been marked by steady price appreciation and consistent outperformance relative to both its sector and the broader market. The stock's ability to maintain levels above key moving averages indicates sustained investor confidence and underlying strength in its business fundamentals.
While the stock's year-to-date performance stands out, it is important to note that longer-term performance data is not currently available, which may affect comprehensive historical comparisons. Nonetheless, the recent trading patterns and market behaviour suggest that Senores Pharmaceuticals has established a solid footing in the competitive Pharmaceuticals & Biotechnology landscape.
In summary, Senores Pharmaceuticals' attainment of an all-time high price level is a noteworthy event, reflecting a combination of favourable market conditions, sectoral strength, and the company's own performance metrics. The stock's current positioning above multiple moving averages and its outperformance relative to the Sensex and sector indices highlight its prominence in the small-cap segment.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
